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Abstract: 
Mitochondria are critical organelles for endocrine health, housing steroid hormone biosynthesis 
and providing energy in the form of ATP for hormone production and trafficking. Mitochondrial 
diseases are multisystem disorders of oxidative phosphorylation that are characterised by 
enormous clinical, biochemical and genetic heterogeneity. Currently mitochondrial disease has 
been linked to greater than 200 monogenic defects encoded on two genomes, the nuclear 
genome and the ancient circular mitochondrial genome located within the mitochondria 
themselves. Endocrine dysfunction is often observed in genetic mitochondrial disease and 
reflects decreased intracellular production or extracellular secretion of hormones. Diabetes 
mellitus is the most frequently described endocrine disturbance in patients with inherited 
mitochondrial disease, but other endocrine manifestations in these patients may include 
growth hormone deficiency, hypogonadism, adrenal dysfunction, hypoparathyroidism and 
thyroid disease. Whilst mitochondrial endocrine dysfunction is frequently in the context of 
multisystem disease, some mitochondrial disorders are characterised by isolated endocrine 
involvement, and it is anticipated that further monogenic mitochondrial endocrine diseases will 
be revealed by genome-wide next generation sequencing approaches. Understanding the 
mitochondrial basis of endocrine disturbance is key to developing innovative therapies. 
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Introduction: 
Mitochondrial diseases are a clinically heterogeneous group of disorders that directly or 
indirectly affect the function of the mitochondrial respiratory chain and oxidative 
phosphorylation (OXPHOS) system (Figure 1) [1]. They are estimated to affect approximately 1 
in 5000 of the population and collectively can be regarded as the most common group of 
inborn errors of metabolism [2]. 
Inherited mitochondrial diseases are caused either by mitochondrial DNA (mtDNA) defects, or 
by defects in the nuclear genes encoding mitochondrial proteins [3]. These defects can affect 
the subunits of OXPHOS complexes, mtDNA translation and maintenance, mitochondrial 
assembly proteins and mitochondrial membrane composition.  
This review focusses on endocrine dysfunction in primary genetic mitochondrial diseases, 
including the clinical features, genetic causes and underlying disease mechanisms. 
 
Systematic review strategy:  
In this article, a review of the current mitochondrial literature was conducted using Medline® 
database searches between August 2015 and January 2016 to retrieve articles related to 
mitochondrial diseases and endocrine dysfunction.  
 
Mitochondrial function: 
Mitochondria are dynamic cellular organelles with multitudinous functions, notably production 
of adenosine triphosphate (ATP), the unit of cellular energy, via OXPHOS. Nicotinamide adenine 
dinucleotide (NADH) and flavin adenine dinucleotide (FADH2), produced mainly in the Krebs 
cycle and from fatty acid oxidation (both of these biochemical pathways are located within the 
mitochondrion), provide substrates to fuel the respiratory chain complexes embedded in the 
inner mitochondrial membrane. Electrons from hydrogen are passed from complexes I and II to 
complex III via the mobile electron carrier coenzyme Q10, and from complex III to cytochrome c, 
another mobile electron carrier, and thence to complex IV, the terminal enzyme of the 
respiratory chain (Figure 1). Complexes I, III and IV act as proton pumps to generate an 
electrochemical gradient across the inner mitochondrial membrane. Finally complex V (ATP 
synthase), powered by the electrochemical gradient, produces ATP from adenosine 
diphosphate (ADP) and inorganic phosphate [4]. Other mitochondrial functions include calcium 
homeostasis, production of reactive oxygen species (ROS) which are essential cellular signalling 
molecules, regulation of apoptosis, and the biosynthesis of all steroid hormones 
(glucocorticoids, mineralocorticoids, oestrogens, progesterone, androgens and calciferols) from 
cholesterol by specialised, tissue-specific mitochondrial enzymes [5]. 
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Mitochondrial genetics: 
Mitochondrial genetics is complicated by the contribution of two genomes: an intrinsic 
organellar genome encoding 37 genes and the extrinsic nuclear genome, which contributes 
~1500 mitochondrially targeted gene products (i.e. 7% of the nuclear exome is dedicated to 
providing the blueprints for mitochondrial proteins). The mitochondrial genome is a maternally 
inherited 16,569 base pair circular double-stranded DNA molecule encoding 13 OXPHOS 
subunits and the 2 ribosomal RNA (rRNA) and 22 transfer RNA (tRNA) molecules needed for the 
intramitochondrial synthesis of these 13 proteins on mitochondrial ribosomes. The nuclear-
encoded components of the ‘mitochondrial proteome’ include proteins needed for replication 
and maintenance of the mitochondrial genome and its expression (including numerous 
transcription and translation factors and ~80 ribosomal proteins), and proteins needed for 
import of proteins and solutes into the mitochondrion, as well as enzymes involved in the Krebs 
cycle, fatty acid beta oxidation and biosynthesis of cofactors and lipids including the steroid 
hormones [6]. 
Mutations of both genomes have now been linked to mitochondrial disease, including 
maternally inherited point mutations and sporadic large-scale rearrangements of the 
mitochondrial genome. Recently next generation sequencing methods have led to an enormous 
increase in nuclear gene defects linked to mitochondrial disease, with >250 gene defects 
already described [7]. The vast majority of these nuclear defects are recessive, although some 
of the late-onset disorders are caused by dominant mutations and a few are X-linked. Thus 
mitochondrial disease may exhibit any mode of inheritance: maternal, autosomal dominant, 
autosomal recessive, X-linked or sporadic. 
Mitochondrial genetics has some unusual properties. Mitochondrial DNA (mtDNA) is 
characterized by a very high copy number, with hundreds or thousands of copies in an 
individual cell, which in turn leads to the phenomena of homoplasmy (where 100% of the 
mtDNA copies within a cell are wild-type or mutant) and heteroplasmy (co-existence of mutant 
and wild-type mtDNA, ranging from 1 to 99% of the mutant mtDNA molecules) [8]. In the case 
of mtDNA mutations, in order for organ dysfunction to occur, a minimum critical proportion of 
mtDNA has to be mutated in a tissue before biochemical deficiency manifests [9]. Typically the 
most affected organs and tissues are those that are highly dependent on aerobic metabolism 
such as muscle, brain and heart. However, mutant heteroplasmy does not necessarily correlate 
with a patient’s clinical manifestations. For example, evaluation of the amount of mutant 
mtDNA present in the sural nerve and thyroid gland of a patient with mitochondrial 
encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) showed >85% 
heteroplasmy, without clinical dysfunction of these tissues [10].  
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Consequences of mitochondrial dysfunction: 
Mitochondrial dysfunction has been reported in heterogeneous diseases and can theoretically 
involve any combination of organ systems, since mitochondria are present in all cells except 
mature erythrocytes [11]. Although some mitochondrial disorders only affect a single organ, 
most involve multiple organ systems with predominant neuromuscular and central nervous 
system features including ptosis, external ophthalmoplegia, proximal myopathy, seizures, 
ataxia, optic atrophy and sensorineural hearing loss, as well as cardiomyopathy and renal and 
hepatic impairment [1]. The incidence of endocrine dysfunction differs in various mitochondrial 
diseases, and appears to be most frequent in syndromes associated with large-scale 
rearrangements of the mtDNA. For example, in Kearns-Sayre syndrome (Table 1), the frequency 
of endocrine disturbance has been reported to range from 35% to 67% [12, 13] Kearns-Sayre 
syndrome is characterized clinically by a triad of progressive external ophthalmoplegia and 
pigmentary retinopathy with age of onset <20 years, variably associated with cardiac 
conduction defects, cerebellar ataxia and other multisystem disease features. Other ‘classical’ 
mitochondrial syndromes include maternally inherited diabetes and deafness (MIDD), 
myoclonic epilepsy with ragged-red fibres (MERRF) and MELAS, all of which are associated with 
point mutations in the mitochondrial genome (Table 1). 
Defective OXPHOS in mitochondrial diseases can lead to decreased intracellular production or 
extracellular secretion of hormones [14]. Impaired ATP synthesis decreases the activity of 
membrane bound calcium ATPase, leading to increased intracellular calcium (Figure 1). Reactive 
oxidative species (ROS) are by-products of energy generation, and require deactivation by 
antioxidant enzymes. ROS production is increased when OXPHOS is impaired and with deficient 
antioxidant defences. Since all steroid hormones are synthesised within mitochondria, lack of 
ATP may lead to impaired hormone production when there is mitochondrial dysfunction [5].  In 
the case of insulin, mitochondrial activity not only provides the necessary ATP required for 
insulin exocytosis, but mitochondria also play a central role in glucose-sensing and inducing 
triggering and amplifying signals to adjust insulin secretion to actual glycaemia [15]. Thus, 
multiple mechanisms may contribute to endocrine dysfunction in mitochondrial disease states 
(Table 2). The following sections will discuss dysfunction of each endocrine organ within the 
context of mitochondrial disease. 
 
Diabetes mellitus: 
Diabetes mellitus is the most well described form of endocrine dysfunction in mitochondrial 
diseases. The association between mitochondrial disease and diabetes is best characterized in 
MIDD, a syndrome caused by the ‘common’ mtDNA point mutation m.3243A>G in the MT-TL1 
gene encoding a mitochondrial tRNA for leucine.  This mutation is also associated with MELAS 
and is present in 1 in 400 people, although the majority are asymptomatic or oligosymptomatic. 
The m.3423A>G mutation is estimated to cause ~0.5 to 2.8% of all cases of diabetes, more 
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commonly in Japanese patients [9, 16-19], making MIDD the most frequently reported 
mitochondrial diabetes in the literature. Diabetes and multiple endocrinopathies are also 
observed in Kearns-Sayre syndrome caused by large-scale mtDNA rearrangements [20, 21]. 
Other mtDNA mutations associated with diabetes include point mutations in the tRNA genes 
MT-TL1 (m.3254C>G, m.3256C>T, m.3264T>G, m.3271T>C), MT-TK (m.8344A>G, m.8356T>C), 
MT-TS2 (m.12258T>C) and MT-TE (m.14709T>C), as well as the m.14577T>C mutation in the 
complex I subunit ND6 [18, 20-22]. Diabetes mellitus has also been reported in nuclear-
encoded mitochondrial diseases caused by autosomal recessive mutations in POLG, RRM2B, 
OPA1 and MPV17, all genes implicated in mtDNA maintenance [9, 20, 23, 24].  
Mitochondrial diabetes can present as type I or type II diabetes [16], and can present insidiously 
at any age, but with an average age of onset of 38 years for the common m.3243A>G mutation, 
and ranging from 40 to 56 years for other mutations [21]. Previous studies suggest that insulin 
deficiency plays a major role in development of diabetes, owing to progressive loss of beta-cells 
within the pancreas. The mechanism leading to mitochondrial dysfunction by the m.3243A>G 
mutation is a reduction of synthesis of mtDNA-encoded proteins, leading to an imbalance 
within the mitochondrion between nuclear and mitochondrial-encoded OXPHOS subunits [25, 
26]. More recent studies demonstrated a combined insulin deficiency and insulin resistance in 
individuals with m.3243A>G and diabetes [27, 28].  Individuals with mitochondrial diabetes 
exhibit a high risk of progression to insulin dependency, unlike other forms of type 2 diabetes. 
This provides further support for the theory of a combined insulin deficiency and resistance. In 
two studies only 13% of diabetic patients with m.3243A>G required insulin at presentation, 
with ~45% progressing to insulin dependence after a mean interval of 4.2 years in the first study 
[21] and 10 years in the second [29].  
Pancreatic exocrine insufficiency is a frequent feature of Pearson syndrome (Table 1), an early-
onset mtDNA deletion disorder. Insulin-dependent diabetes mellitus in infancy has been 
described in some patients, with or without concurrent exocrine pancreatic insufficiency [12]. 
Onset of diabetes ranged from the neonatal period to 21 months [30-32]. Autopsy revealed 
fibrosis and atrophy of the exocrine and endocrine pancreas in two cases [31, 32], and 
hypoplasia of the pancreas in one case with diabetes but without symptoms suggestive of 
malabsorption [12].  
Pattern recognition and a high level of suspicion are crucial to identifying patients with 
mitochondrial disease. Multi-systemic disease manifestations may precede onset of diabetes. 
Other organs with high metabolic activity are usually affected, including the brain, muscles, 
myocardium and kidneys. As in MIDD, a combination of sensorineural deafness and a family 
history of maternal inheritance should raise suspicion. Hearing loss usually develops in early 
adulthood (range 2-61 years) [29]. The most common ophthalmic feature is macular retinal 
dystrophy, observed in 86% of adult patients in a multicentre prospective study of MIDD [29]. 
Other clues pointing towards mitochondrial diabetes include a lower than average BMI [21, 33]. 
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Patients with m.3243A>G have not been found to carry islet cell or GAD antibodies [9], and the 
phenotype of diabetes in MIDD appears to be independent of HLA-DQ phenotype [34].  
With regards to the complications of diabetes, retinopathy, neuropathy and renal failure were 
more prevalent in a cohort of patients with m.3243A>G compared to patients with type 1 or 2 
diabetes in the UK [21].  Cardiac manifestations were also more frequent in MIDD patients with 
diabetes compared with other diabetic patients. This includes left ventricular hypertrophy in 
absence of hypertension, cardiac autonomic neuropathy and reduced heart rate variability 
without coronary artery disease [35-38]. This implies that pre-existent mitochondrial 
dysfunction in the end organs predispose to these macro and microvascular complications [9, 
21].  
As aforementioned, patients usually present with non-insulin dependent diabetes, but a 
significant proportion of patients rapidly progress to insulin dependency. The drug of choice for 
non-insulin dependent diabetes is sulphonylurea [9]. Metformin and thiazolidinediones should 
ideally be avoided since they inhibit mitochondrial complex I and may worsen lactic acidosis 
[20, 39, 40]. End organ involvement should be carefully monitored. With the high risk of renal 
involvement, early use of angiotensin-converting enzyme inhibitors in case of renal involvement 
and a tight control of hypertension is recommended [18]. Statins should be used judiciously in 
view of their potential for inducing myositis. Monitoring creatine kinase levels pre and post 
treatment is recommended during statin treatment [9].  
 
Short stature and growth hormone deficiency 
Short stature is commonly described in mitochondrial diseases, and was a presenting feature in 
48% of a cohort of 96 MELAS patients in Japan [41]. Fifty-five percent of patients developed 
short stature during their disease course. As might be expected, short stature was a more 
common presenting symptom in patients with juvenile-onset MELAS compared to adult-onset 
MELAS (60% versus 29%). Review of height and weight data of 24 children and adolescents with 
a confirmed diagnosis of mitochondrial disease revealed short stature (overall height SDS -1.97; 
95% confidence intervals -2.72 to -1.23), and a lower body mass index (SDS -1.07 ; 95% 
confidence intervals -1.69 to - 0.07) [42]. Faltering growth was also noted in 28% of the 
Japanese MELAS cohort [41]. Whilst short stature may arise from any severe mitochondrial 
disease with onset in infancy or early childhood, it has been reported most frequently in 
association with cytochrome oxidase (complex IV) deficiency, including mutations in the 
NDUFA4 subunit and the assembly factors SURF1, COX10 and LRPPRC [43-46].  Growth failure 
was reported in 95% of patients in a multicentre cohort of children with Leigh syndrome 
secondary to SURF1 deficiency (complex IV assembly defect) [45], compared to 52% of patients 
with Leigh syndrome caused by LRPPRC mutations (leading to impaired mitochondrial 
translation of a complex IV subunit) [46]. Short stature is also recognised in Kearns-Sayre 
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syndrome, with reported rates ranging from 38% to 63% [47, 48]. However, the precise 
mechanism for growth failure has not been well established.  
Growth hormone deficiency has been described in multiple case reports and case series with 
MELAS [10, 49-53], decreased complex II activity [54], mtDNA deletion disorders [12, 13, 55-58], 
and various mitochondrial diseases without genetic confirmation [59, 60]. Growth hormone 
deficiency and/or short stature has also been documented in nuclear-encoded defects of 
mitochondrial translation, e.g. mutations in IARS2, MTFMT and C12orf65 [61-63] .  
Hypothalamo-pituitary dysfunction has been proposed as the mechanism for growth hormone 
deficiency in mitochondrial disease. Previous hypotheses for hypothalamic dysfunction include 
chronic ischaemia and energy deficiency of the diencephalon due to mitochondrial abnormality 
of the region [51]. One MELAS patient with growth hormone deficiency had high (95%) levels of 
mutant mtDNA in the hypophysis [10]. This patient also had anterior pituitary dysfunction in 
addition to hypothalamic impairment.  Non-specific degenerative changes and cerebral atrophy 
were reported in patients with mitochondrial disease and growth hormone deficiency [10, 13, 
50]. The pituitary gland was described to be normal despite severe cerebral and cerebellar 
atrophy in one patient with MELAS presenting with multiple endocrinopathies suggestive of 
hypothalamic dysfunction [50]. In contrast, the only MRI abnormality observed in a 10 year old 
boy with MELAS and complete growth hormone deficiency was bilateral T2-weighted 
hyperintense signal in the globus pallidus and in the midbrain tegment [57].   
Most patients reported with confirmed growth hormone deficiency were started on growth 
hormone treatment, and short term improvement in growth has been noted without adverse 
effects [12, 49, 54, 56, 59, 60]. However long term effects of growth hormone in this population 
are not clear [64]. Although most described patients did not suffer any adverse effects from 
growth hormone treatment, Romano et al [60] reported two patients whose condition 
worsened on growth hormone treatment, of which one patient did not have growth hormone 
deficiency. One patient developed hypotonia, loss of language and memory skills, and the other 
developed severe hypotonia, cerebellar ataxia and loss of speech and pyramidal signs after 
three months of treatment. Both patients showed improvement in their condition with 
discontinuation of growth hormone therapy. This was hypothesized to be due to the fact that 
growth hormone is a stimulator of mitosis, and may increase energy demand for cell 
proliferation. However, it is difficult to draw firm conclusions on such small numbers. There are 
also reports of patients with growth hormone deficiency who did not respond to growth 
hormone treatment [60, 65].  
Growth hormone deficiency has not been identified in some mitochondrial patients with short 
stature [13, 60, 66]. Many patients have delayed or absent puberty, and this is also thought to 
be contributory to the reported short stature, especially if they present during adolescence.  
In summary, short stature is a common feature of mitochondrial disease, and growth hormone 
deficiency has been well described, particularly in mtDNA deletion syndromes and MELAS. 
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However, many patients with short stature do not have growth hormone deficiency. Brain 
imaging findings are non-specific in growth hormone deficient patients, and have not been 
reported to show pituitary abnormalities. Growth hormone therapy has been effective in 
improving height gain in some patients without adverse effects.  However, efficacy is variable 
and in view of potential adverse effects in this condition, growth hormone should be used with 
caution and close monitoring is recommended.  
 
Hypogonadism: 
Both hypergonadotrophic and hypogonadotrophic hypogonadism have been described in 
patients with mitochondrial disease. Thirty-eight percent of a cohort of 21 patients with 
mitochondrial myopathy and external ophthalmoplegia were reported to have various signs of 
hypogonadism [13]. Hypergonadotrophic hypergonadism can also occur due to specific 
mitochondrial steroidogenic defects affecting the testis or ovary (e.g. STAR, CYP11A1, HSD3B2 
mutations) but detailed discussion of these conditions is beyond the scope of this review. 
Hypogonadotrophic hypogonadism due to hypothalamic dysfunction has been more frequently 
described than primary ovarian or testicular insufficiency in patients with MELAS, MERRF and 
Kearns-Sayre syndromes. Poor development of secondary sexual characteristics and low serum 
LH and FSH concentrations have been reported [13, 53, 67-70]. Not all cases had delayed 
pubertal onset. Some form of pubertal development appeared to have occurred in these 
patients, who subsequently developed oligomenorrhoea or secondary amenorrhoea. Primary 
ovarian insufficiency was excluded in some of these cases [13].  
Hypergonadotrophic hypogonadism has been described in mtDNA depletion syndrome caused 
by mutations in C10orf2 (encoding the twinkle DNA helicase) [71]. Two of 23 patients with 
infantile onset spinocerebellar ataxia (IOSCA) caused by recessive C10orf2 mutations, both 
compound heterozygotes for the p.Y508C and p.A318T mutations, were noted to have 
hypergonadotrophic hypogonadism by teenage years alongside their neurological symptoms 
[71]. Other mitochondrial causes of hypergonadotrophic hypogonadism include POLG 
mutations [72-74], mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) [75], 
primary coenzyme Q10 deficiency [76], Leigh syndrome caused by LRPPRC mutation [46], and 
one patient with mutations in MRPS7 encoding a mitochondrial ribosomal protein [77]. A novel 
“ovarioleukodystrophy” has been linked to mutations in AARS2 (encoding mitochondrial alanyl-
tRNA synthetase), where all females with late-onset disease present with ovarian insufficiency, 
followed by progressive leukoencephalopathy [78]. Thus all nuclear-encoded defects causing 
hypergonadotrophic hypogonadism appear to be associated with impaired mtDNA 
maintenance or gene expression.  
Mitochondrial primary ovarian insufficiency and premature menopause have been described 
most frequently in patients with the dominantly inherited POLG mutation p.Y955C, including 
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four women with progressive external ophthalmoplegia and early menopause before the age of 
35 years and a three generation pedigree with progressive external ophthalmoplegia and 
premature ovarian insufficiency [72, 73]. Other POLG mutations associated with primary 
ovarian insufficiency in single cases include p.N468D/p.A1105T [72], p.R943H [74] and p.R953C 
[79]. Of note, all the patients had accompanying neurological features.  
The occurrence of ovarian mtDNA deletion and menstrual irregularity has been observed in 
menopausal women [80]. The mature oocyte has the highest mtDNA copy of all cells [81], and is 
likely to be more sensitive than other tissues to a reduced DNA polymerase gamma activity 
[73]. An inadequate pool of primordial follicles, impaired oocyte maturation and accelerated 
follicle apoptosis due to dysfunction of cytochrome oxidase and increased ROS production  
have all been hypothesized to be the cause of ovarian insufficiency in the aging oocyte [82, 83].  
Two studies aimed to elucidate whether POLG mutations could be responsible for isolated 
primary ovarian insufficiency in a more general population. Tong et al [79] evaluated 201 46,XX 
women with ovarian insufficiency for five common POLG mutations associated with ovarian 
insufficiency, and found only one with a POLG mutation (p.R943H), whilst Duncan et al did not 
identify any of four common POLG mutations in a cohort of 57 women with premature ovarian 
insufficiency [84]. Thus, POLG mutations do not appear to be a common genetic aetiology for 
this form of infertility. Moreover, almost all women had associated neurological features, 
suggesting that POLG mutation testing is only indicated where there is clinical suspicion of a 
possible mitochondrial disorder.  
Perrault syndrome is characterised by ovarian dysgenesis and sensorineural deafness [85]. 
Biallelic pathogenic variants have now been reported in five genes in individuals with Perrault 
syndrome. Although the first reported gene HSD17B4 encodes a peroxisomal enzyme (17-beta 
hydroxysteroid dehydrogenase type 4, involved in fatty acid beta-oxidation and steroid 
metabolism), the remaining four encode mitochondrial proteins. Three of these are involved in 
maintenance and expression of the mitochondrial genome: C10orf2 [86], HARS2 (encoding 
mitochondrial histidyltRNA synthetase), and LARS2 (encoding mitochondrial leucyl-tRNA 
synthetase) [85, 87-90]. The fifth gene, CLPP, encodes a serine protease that is an important 
component of the mitochondrial quality control system. Associated neurological symptoms in 
patients with CLPP mutations include truncal and cerebellar ataxia and lower limb spasticity 
[89]. Patients with LARS2 mutations had apparently normal neurology and intelligence [88].   
Mitochondrial dysfunction has been less frequently linked to male fertility in the literature. 
Both hypogonadotrophic and hypergonadotrophic hypogonadism have been described in male 
patients with MNGIE [69, 75].   It was postulated that POLG mutations might be a cause of male 
infertility, but more recent studies have not confirmed an association between POLG mutations 
and oligo-azoospermia [91-93]. There was no testicular dysfunction in male patients with 
Perrault syndrome or AARS2 mutations, despite the presence of ovarian insufficiency in female 
patients with the same mutations [78, 88].  
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In summary, hypogonadism may occur in patients with mitochondrial disease, manifesting 
either as hypothalamic dysfunction or as end organ insufficiency. Primary ovarian insufficiency 
may be the presenting feature of mitochondrial disease, preceding onset of neurological 
symptoms.  
 
Adrenal dysfunction:  
Mitochondrial abnormalities of the adrenal axis were initially described in mtDNA deletion 
syndromes such as Kearns-Sayre and Pearson syndromes. A total of 12 case reports identified 
primary adrenal insufficiency in 14 patients with genetically confirmed mitochondrial disease 
[94], of whom five had Kearns-Sayre syndrome [14, 95-98], and two Pearson syndrome [30, 99]. 
More recently primary adrenal insufficiency was reported in a child with a MELAS phenotype, 
atypically associated with the m.8344A>G mutation, more commonly linked to MERRF 
syndrome [100].  
Several nuclear-encoded mitochondrial defects are associated with adrenal dysfunction. 
However, since these do not primarily affect OXPHOS and a detailed review of these conditions 
is provided elsewhere [5], they will only be discussed briefly here. Mutations in STAR (encoding 
steroidogenic acute regulatory protein) affect cholesterol transport across the mitochondrial 
membrane and defects in CYP11A1 (encoding P450 cholesterol side chain cleavage) affect 
pregnenolone production. Severe defects in both these factors cause early-onset adrenal 
insufficiency, often with impaired gonadal sex steroid production. However, milder forms can 
present with isolated adrenal insufficiency in childhood [101]. Other steroidogenic enzymes 
localised to the mitochondria are 3β-hydroxysteroid dehydrogenase, 11β-hydroxylase and 
aldosterone synthase, which are involved in mineralocorticoid synthesis. More recently 
mutations in NNT, an antioxidant defence gene encoding nicotinamide nucleotide 
transhydrogenase, and TXNRD2, encoding thioredoxin reductase 2 (also part of the 
mitochondrial antioxidant defence system), have been associated with familial glucocorticoid 
deficiency [102, 103]. In view of the severe nature of these defects, it is somewhat surprising 
that the only clinical manifestation was isolated glucocorticoid deficiency. Further studies are 
needed to determine why the adrenal gland appears to be particularly susceptible to oxidative 
stress and whether any other clinical features develop with time [104].  
Other nuclear-encoded defects associated with adrenal insufficiency include defective complex 
I assembly caused by NDUFAF5 mutations [105], and abnormalities of mitochondrial 
translation, import and mtDNA replication. One of two sisters with mutations in the MRPS7 
mitochondrial ribosomal subunit had primary adrenal insufficiency and primary hypogonadism 
at 16 years [77], and adrenal insufficiency was also reported in a patient with combined 
respiratory complex deficiencies due to a homozygous QRSL1 mutation [7].  A 19 year old 
woman with mitochondrial encephalopathy caused by mutations in GFER, encoding a 
component of the mitochondrial protein import system, had primary adrenal insufficiency 
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associated with congenital cataracts and lactic acidosis [94].  Finally, identical twins with a 
multisystem disorder, including polyendocrinopathy (diabetes, adrenal insufficiency and 
hypothyroidism), bilateral basal ganglia infarcts, headaches, seizures and psychiatric problems, 
were reported to have a heterozygous POLG mutation p.G517V [23]. However, it has since been 
suggested that p.G517V is a neutral polymorphism [106], so the underlying cause of 
mitochondrial disease in this family remains unclear.  
Adrenal insufficiency with hyperpigmentation and hyponatraemia can be the first presenting 
symptom prior to onset of other symptoms such as neurological symptoms, deafness and other 
endocrine dysfunction [100, 107]. However, age at onset of adrenal insufficiency varies widely, 
ranging from 7 months to 32 years, and can be preceded by other disease features.   
Impaired mitochondrial ATP production and/or oxidative stress are the most likely explanations 
for the decreased capacity of adrenocortical hormone production. A limited autopsy was 
performed in one case and showed a trace amount of scar tissue replacing the adrenal glands 
[96]. Although adrenal insufficiency was a dominant feature in this patient, the mutant load 
was only 65% in the adrenal glands, compared to 95% in the liver, without any clinical hepatic 
disease. Thus, the degree of mutant heteroplasmy among tissues does not necessarily correlate 
with clinical manifestations.  
Interestingly, hypothalamic-pituitary dysfunction as a cause of secondary cortisol insufficiency 
has only been reported once in a case with MERRF [108]. Growth hormone and gonadotrophins 
appear to be the predominant hormonal deficits in mitochondrial patients with pituitary or 
hypothalamic dysfunction.  
 
Hypoparathyroidism: 
Hypoparathyroidism, although not common, is well recognized in mitochondrial diseases in 
particular Kearns-Sayre syndrome. In a literature survey conducted in 1992, Harvey et al 
retrospectively reviewed endocrine dysfunction in 226 cases fitting the criteria for Kearns-Sayre 
syndrome [48]. Fourteen of 226 (6%) of cases had hypoparathyroidism, although a mixture of 
probable cases and a small number of cases with onset after the age of 20 years were included. 
In a more recent series three of 34 (9%) of children with single mtDNA deletion disorders had 
hypoparathyroidism [12]. In two Kearns-Sayre patients with hypoparathyroidism, one patient 
had absent glands at autopsy [109], and the other had only one gland confirmed by microscopic 
examination [110]. Four children with Kearns-Sayre syndrome presented hypoparathyroidism 
and deafness as initial major manifestations, with hypocalcaemic tetany starting between 6 and 
13 years [111]. Deafness preceded the onset of hypoparathyroidism in two patients. 
Hypoparathyroidism was the initial presentation at age three years, prior to onset of growth 
failure and hearing deficit, in another case [112]. Other patients had other accompanying 
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features including growth failure and neurological symptoms, ptosis, ophthalmoplegia, 
myopathy and sensorineural hearing loss.  
Renal tubulopathy is common in patients with Kearns-Sayre disease, leading to significant 
calcium, magnesium and potassium losses in the urine. Severe hypomagnesaemia suppresses 
parathyroid hormone secretion and may induce some parathyroid hormone resistance, leading 
to further hypocalcaemia [113]. Parathyroid hormone concentrations remained low despite 
magnesium supplementation in two cases [114, 115]. Co-existing renal tubular dysfunction and 
hypoparathyroidism may contribute to disturbances in calcium homeostasis in patients with 
Kearns-Sayre syndrome.  
Apart from Kearns-Sayre syndrome, hypoparathyroidism has been documented in one patient 
with MIDD with the classical m.3243A>G mutation [116].  
Multiple endocrinopathies have been documented in case reports of patients with Kearns-Sayre 
syndrome with hypoparathyroidism, in particular in association with diabetes mellitus [111, 
112, 117, 118]. Hypoparathyroidism appears to be rare in adult forms of mitochondrial disease, 
and seems most likely to occur in severely affected patients who present with multi-systemic 
disease in childhood [9]. The authors hypothesized that the heteroplasmic threshold for 
dysfunction of the parathyroid gland is only reached in cases where very high levels of 
heteroplasmy are present in most tissues. The incidence of other endocrine abnormalities also 
appeared to be more frequent in patients with hypoparathyroidism, including diabetes mellitus 
(28% versus 12%), thyroid disease (14% versus 2%) and hypogonadism (35% versus 18%), 
however the sample sizes were too small to reach robust conclusions [48].  
In summary mitochondrial hypoparathyroidism is associated with severe multisystem disease 
and is often seen in combination with other endocrinopathies in Kearns-Sayre syndrome.  
 
Thyroid disease:  
Thyroid dysfunction has been infrequently reported in mitochondrial disease, and the 
prevalence appears to be similar to the background population rate [9]. However, numerous 
case reports have documented hypothyroidism developing in a heterogeneous group of 
patients, including 15% (6 out of 40) of an adult cohort with late onset chronic progressive 
external ophthalmoplegia, and was more frequent than diabetes mellitus (5%) in this cohort 
[119]. Hypothyroidism has been described in patients with mtDNA deletions including Kearns-
Sayre syndrome [12, 48, 55]. In the literature review by Harvey et al in 1992, 7 of 226 cases (3%) 
with probable Kearns-Sayre syndrome had thyroid disease [48]. Types of thyroid dysfunction 
reported include compensated hypothyroidism, multinodular goitre, congenital thyroid 
malformation, and one patient with papillary carcinoma. Central hypothyroidism has been 
described in a patient with MELAS [53]. 
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Very few nuclear-encoded mitochondrial defects have been linked to thyroid dysfunction. As 
discussed above, a polyendocrinopathy including diabetes, adrenal insufficiency and 
hypothyroidism was reported in twins with a heterozygous POLG mutation p.G517V [23], but 
the pathogenic significance of this mutation has since been questioned [106]. Recently 
recessive mutations in PTRH2, encoding mitochondrial peptidyl-tRNA hydrolase 2, have been 
associated with a complex multisystem disorder including hypothyroidism and exocrine 
pancreatic insufficiency, associated with intellectual disability, microcephaly, progressive ataxia, 
distal muscle weakness, peripheral demyelinating sensorimotor neuropathy, growth 
retardation, sensorineural deafness and liver fibrosis [120].  
In summary, thyroid dysfunction is common in the general population, and it is currently 
unknown whether there is any causal relationship between mitochondrial disease and thyroid 
dysfunction. There are inadequate data to suggest whether thyroid dysfunction occurs more 
frequently in mitochondrial disease compared to the background population. However, as 
subclinical hypothyroidism can be asymptomatic, the incidence of hypothyroidism is probably 
underestimated in this group of patients.  
 
Conclusions:  
Mitochondrial diseases are multi-systemic diseases, and can present with endocrine 
dysfunction, in particular in the mtDNA deletion syndromes such as Kearns-Sayre syndrome and 
disorders associated with mtDNA point mutations affecting tRNA genes, such as MIDD, MELAS 
and MERRF. Recently endocrine dysfunction has been reported in a large number of nuclear-
encoded mitochondrial defects, particularly those affecting maintenance of mtDNA or 
mitochondrial translation. The underlying disease mechanisms leading to mitochondrial 
endocrine dysfunction remain obscure. Failure to synthesise and/or secrete hormones 
secondary to lack of ATP and/or oxidative stress have been implicated, but other possible 
mechanisms include impaired cellular signalling and calcium handling. Further studies in animal 
and patient cell models of mitochondrial disease are needed in order to tease out these 
mechanisms in more detail. 
Diabetes mellitus is well recognized in mitochondrial diseases, especially in the MIDD 
syndrome. Gonadal insufficiency, in particular ovarian insufficiency, has also been reported in 
various mitochondrial disorders. Other end organ dysfunction such as primary adrenal 
insufficiency and hypoparathyroidism are less frequently described. Multiple endocrinopathies 
can include hypothalamic dysfunction with multiple pituitary hormone deficiencies. Patients 
with hypoparathyroidism and primary adrenal insufficiency have also been found to have other 
endocrinopathies.  
Endocrine dysfunction can sometimes be the initial presenting symptom preceding hearing 
impairment and other neurological manifestations of mitochondrial diseases. Physicians should 
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have a high level of suspicion in patients presenting with endocrine abnormalities and multi-
systemic diseases for the possibility of an underlying mitochondrial disease (Figure 3). In 
parallel, physicians managing patients with mitochondrial diseases should be aware of possible 
multiple endocrine complications and regularly screen for them in at risk patients, since these 
are potentially treatable aspects of these incurable disorders.  
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Figure Legends 
Figure 1: Oxidative Phosphorylation 
The respiratory chain and oxidative phosphorylation system are embedded in the inner mitochondrial 
membrane, and represent the major site of ATP production within the cell. Transfer of electrons derived 
from NADH and FADH2 is coupled to proton pumping to generate an electrochemical gradient across the 
inner mitochondrial membrane. This electrochemical gradient is harnessed by ATP synthase to drive the 
synthesis of ATP from ADP and inorganic phosphate (Pi). Five different protein complexes are involved: 
NADH-ubiquinone oxidoreductase (Complex I), succinate ubiquinone oxidoreductase (Complex II), 
ubiquinone cytochrome c oxidoreductase (Complex III), cytochrome c oxidase (Complex IV) and ATP 
synthase (Complex V), in addition to two mobile electron carriers: coenzyme Q10 (Q) and cytochrome c 
(Cyt c). 
 
 
 
Figure 2: Endocrine Dysfunction in Mitochondrial Disease and their Associated Gene 
Defects 
 
Figure 3: Flowchart for Diagnosis of Endocrine Manifestations of Mitochondrial 
Disease  
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Box 1: Key Points 
• Respiratory chain function and oxidative phosphorylation are affected in primary 
mitochondrial diseases.  
• Mitochondria are present in all cells except mature erythrocytes, and defects in 
mitochondrial energy metabolism can lead to multi-system organ dysfunction.  
• Since all steroid hormones are synthesised within mitochondria, lack of ATP generated from 
mitochondrial dysfunction can lead to impaired hormone production.  
• Endocrine abnormalities are well recognised complications in mitochondrial disorders, 
observed most frequently in syndromes caused by large-scale mtDNA rearrangements such 
as Kearns-Sayre syndrome. 
• Hormonal insufficiency from endocrine organ failure can occur, including diabetes mellitus, 
ovarian failure, adrenal insufficiency and hypoparathyroidism. 
• Endocrine dysfunction may be the presenting feature of mitochondrial disease, preceding 
neurological symptomatology.  
• Mitochondrial disease should be suspected in a patient presenting with multi-systemic 
disease and endocrine abnormalities.  
 
Table 1:  Examples of Mitochondrial Syndromes 
Mitochondrial 
syndromes 
Clinical phenotype Associated gene 
defects 
Inheritance 
Alpers-Huttenlocher Infantile onset of 
developmental delay or 
regression, intractable 
epilepsy, +/- liver failure 
POLG, FARS2, 
NARS2, PARS2 
Autosomal recessive 
*Kearns-Sayre syndrome  Progressive external 
ophthalmoplegia, retinitis 
pigmentosa, 
cardiomyopathy, heart block 
mtDNA deletion Usually sporadic 
Leber hereditary optic 
neuropathy 
(LHON) 
Optic neuropathy mtDNA point 
mutations (most 
commonly m. 
m.11778G>A, 
m.3460G>A and 
m.14484T>C) 
Maternal 
Leigh syndrome Subacute relapsing 
encephalopathy of infantile 
onset 
>75 genes Maternal; Autosomal 
recessive; X-linked 
Mitochondrial DNA 
depletion syndromes 
Hepatocerebral, myopathic 
and encephalopathic 
variants 
POLG, DGUOK, 
MPV17, C10orf2, 
TK2, SUCLA2, 
SUCLG1, RRM2B, 
FBXL4, MGME1 
Autosomal recessive 
*Mitochondrial Stroke-like episodes before MT-TL1 Maternal 
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encephalomyopathy with 
lactic acidosis and stroke-
like episodes  
(MELAS) 
40 years, seizures, migraine, 
cognitive decline, lactic 
acidosis, childhood onset 
muscle weakness 
(m.32423A>G in 80% 
cases) and other 
mtDNA point 
mutations  
Myoclonic epilepsy 
myopathy sensory ataxia  
(MEMSA) 
Myopathy, seizures, 
cerebellar ataxia 
POLG Autosomal recessive 
Myoclonic epilepsy with 
ragged-red fibers  
(MERRF) 
Myoclonus, seizures, 
cerebellar ataxia, myopathy 
MT-TK (m.8344A>G) 
and other mtDNA 
point mutations, 
POLG 
Maternal; Autosomal 
recessive 
*Maternally inherited 
diabetes and deafness 
(MIDD) 
Diabetes and deafness MT-TL1 (m.3243A>G) 
 
Maternal 
Mitochondrial 
neurogastrointestinal 
encephalopathy 
(MNGIE) 
Progressive gastrointestinal 
dysmotility, 
ophthalmoplegia, 
leukoencephalopathy, 
peripheral neuropathy 
TYMP 
(similar symptoms 
may occur with 
POLG, RRM2B, MT-
TL1, MT-TV 
mutations) 
Autosomal recessive; 
Maternal 
Neurogenic weakness 
with ataxia and retinitis 
pigmentosa 
(NARP) 
Late childhood or adult 
onset peripheral 
neuropathy, ataxia, 
retinopathy 
MT-ATP6 (most 
commonly 
m.8993T>G/C) 
Maternal 
*Pearson syndrome Sideroblastic anaemia, 
pancytopenia, exocrine 
pancreatic dysfunction  
mtDNA deletion Usually sporadic 
*Perrault syndrome  Premature ovarian 
insufficiency, sensorineural 
hearing loss 
C10orf2, CLPP, 
HARS2, LARS2 
Autosomal recessive 
Progressive external 
ophthalmoplegia (PEO) 
Progressive external 
ophthalmoplegia +/- skeletal 
myopathy 
mtDNA deletions; 
mtDNA mutations; 
POLG, C10orf2, 
RRM2B, SLC25A4 
Sporadic; maternal; 
autosomal dominant 
Sensory ataxia, 
neuropathy, dysarthria, 
ophthalmoparesis 
(SANDO) 
Ataxia, peripheral 
neuropathy, eye movement 
disorders, epilepsy, cognitive 
impairment, psychiatric 
symptoms, involuntary 
movements (part of ataxia 
neuropathy spectrum) 
 
POLG, C10orf2, OPA1 Autosomal recessive 
*Endocrine dysfunction commonly described 
Table 2: Gene defects associated with endocrine manifestations in mitochondrial disease  
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Endocrine 
manifestation 
Gene defect(s) Inheritance 
mode 
Molecular mechanism 
Diabetes mellitus MT-TL1, MT-TK, MT-TS2, MT-TE 
Large-scale mtDNA deletion 
POLG, RRM2B, OPA1, MPV17 
Maternal 
Sporadic 
Impaired translation 
Impaired translation 
Impaired mtDNA maintenance 
Short stature & 
Growth hormone 
insufficiency 
MT-TL1, MT-TK  
Large-scale mtDNA deletion 
IARS2, MTFMT, C12orf65 
NDUFA4, SURF1, COX10, LRPPRC  
ECHS1 
Maternal 
Sporadic 
AR 
AR 
AR 
Impaired translation 
Impaired translation 
Impaired translation 
Impaired complex IV 
Oxidative stress 
Hypergonadotrophic 
hypogonadism 
STAR, CYP11A1, HSD3B2 
 
C10orf2, POLG, TYMP 
LRPPRC, MRPS7, AARS2 
AR 
 
AR 
AR 
Impaired mitochondrial 
steroidogenesis 
Impaired mtDNA maintenance 
Impaired translation 
Hypogonadotrophic 
hypogonadism 
MT-TL1, MT-TK 
Large-scale mtDNA deletion 
TYMP 
Maternal 
Sporadic 
AR 
Impaired translation 
Impaired translation 
Impaired mtDNA maintenance 
Primary ovarian 
insufficiency or 
premature 
menopause 
POLG 
C12orf65, LRPPRC 
COX10 
CLPB 
AD or AR 
AR 
AR 
AR 
Impaired mtDNA maintenance 
Impaired translation 
Impaired complex IV assembly 
Impaired mitochondrial quality 
control 
Perrault syndrome C10orf2 
HARS2, LARS2 
CLPP 
AR 
AR 
AR 
Impaired mtDNA maintenance 
Impaired translation 
Impaired mitochondrial quality 
control 
Adrenal insufficiency STAR, CYP11A1, HSD3B2 
 
Large-scale mtDNA deletion 
MT-TK 
MRPS7, QRSL1 
NDUFAF5 
GFER  
NNT, TXNRD2 
AR 
 
Sporadic 
Maternal 
AR 
AR 
AR 
AR 
Impaired mitochondrial 
steroidogenesis 
Impaired translation 
Impaired translation 
Impaired translation 
Impaired complex I assembly 
Impaired mitochondrial import 
Oxidative stress 
Hypoparathyroidism Large-scale mtDNA deletion  
MT-TL1 
Sporadic 
Maternal 
Impaired translation 
Impaired translation 
Hypothyroidism MT-TL1 
PTRH2 
Maternal 
AR 
Impaired translation 
Impaired translation 
 
Key: AD = autosomal dominant; AR = autosomal recessive; Perrault syndrome = ovarian dysgenesis and 
sensorineural hearing loss 
 


Patient seen in endocrine clinic 
with symptoms and signs 
suspicious of a specific 
mitochondrial syndrome e.g. MIDD 
or Kearns-Sayre syndrome 
Refer to 
mitochondrial 
clinic 
Patient with clinically 
confirmed 
mitochondrial disease 
in mitochondrial clinic 
Abnormal 
result 
* e.g. m.3243A>G analysis in MIDD syndrome, screen for mtDNA deletions in Kearns-Sayre syndrome 
Diagnosis confirmed 
Regularly screen for 
endocrine manifestations: 
fasting glucose, HbA1c, 
thyroid function, cortisol, 
ACTH, calcium, magnesium 
and phosphate, PTH, (IGF1 
and IGFBP3 if short stature) 
Refer to 
endocrine 
clinic 
Direct genetic analysis* 
